The Former Head of the Human Genome Project Joins InSilico Medicine, Inc. in the War on Aging as the Chair of the SAB

The Former Head of the Human Genome Project Joins InSilico Medicine, Inc. in
the War on Aging as the Chair of the SAB

Charles Cantor, PhD, professor emeritus at Boston University and former
principal scientist of the Human Genome Project joined the Science Advisory
Board of InSilico Medicine, Inc.

BALTIMORE, Md., June 4, 2014 (GLOBE NEWSWIRE) -- via PRWEB - InSilico
Medicine, Inc. announced today that Charles Cantor, Ph.D. will chair its
Scientific Advisory Board.

Dr. Cantor, one of the leaders of the Human Genome Project, has published more
than 400 peer-reviewed articles, authored and co-authored more than 50 U.S.
and international patents. He is also an author of the first genomics
textbook, "Genomics: The Science and Technology of the Human Genome Project"
and the three-volume textbook "Biophysical Chemistry".

"Professor Cantor's discoveries and leadership are already helping save lives
and improve human health span. What is less known is his interest in areas
related to aging including the complex and multi-year research projects in
isotopically-fortified organic compounds and advanced diagnostics using the
cell-free nucleic acids. He is the role model for the many research scientists
aspiring to utilize resources available in the private sector, accelerate
scientific research without the many formal constraints and budgetary
limitations of academia and turn their discoveries into practical projects. We
are honored to have Charles join our advisory board", said Alex Zhavoronkov,
PhD, CEO of InSilico Medicine, Inc.

Dr. Cantor is the co-founder of Sequenom, Inc, a company engaged in
non-invasive prenatal diagnostics and co-founder of Retrotope, a company
developing isotopically-fortified organic compounds to bolster stress
resistance and combat age-related diseases and acts as a consultant for
several companies within the biotechnology industry. He is professor emeritus
at the Boston University, distinguished adjunct professor at the University of
California Irvine and adjunct professor at the Moscow Institute of Physics and
Technology and at Scripps Research Institute. Dr. Cantor was previously the
chair and professor of the department of biomedical engineering and
biophysics, and director of the Center for Advanced Biotechnology at Boston
University, and his research laboratory remains active.

"Aging is one of the most pressing problems facing the economies of the
developed countries and there is an urgent need for new ways to increase
productive longevity and screening the known drugs for their geroprotective
properties and personalizing anti-cancer and aging-suppressive regiments using
genetic and epigenetic analysis is one of the low hanging fruits in applied
aging research. I am pleased to join the SAB of this international team
dedicated to develop working solutions for both aging and age-related
diseases", said Charles Cantor, PhD, chair of the Science Advisory Board of
InSilico Medicine, Inc.

Dr. Cantor was the chairman of Genetics and Development at Columbia University
College of Physicians & Surgeons, and Professor of Molecular Biology,
University of California, Berkeley.

He earned his bachelor's degree in chemistry at Columbia College, and his
doctorate at the University of California Berkeley.

About InSilico Medicine, Inc.

Insilico Medicine, Inc. is a Baltimore-based bioinformatics and drug discovery
company specializing in cancer and aging research and personalized medicine in
age-related diseases. The company is developing models and softwares to
predict the efficacy of the various targeted drugs in oncology and
extrapolated these methods to evaluate the possible geroprotective properties
of the many drugs with known molecular targets. The mission of InSilico
Medicine is to find working solutions to treat, cure and prevent age-related
diseases and aging itself through excellence in knowledge management, machine
learning and bioinformatics, relentless pursuit for new drug, omics and
clinical outcomes data, development of reliable in silico drug screening
methods, novel validation approaches and strong international partnerships in
personalized medicine. This mission will be achieved within the regulatory
frameworks as well as the legal and ethical boundaries and by working with the
outstanding scientists, academic and medical institutions and pharmaceutical
companies of impeccable credibility. For more information please visit
http://www.InSilicoMedicine.com .

Contact @ Insilico Medicine, Inc.:

InSilico Medicine, Inc.
Johns Hopkins University Eastern Campus
B301, 1101 East 33rd Street
Baltimore, MD 21218

Qinsong Zhu, PhD
Chief Operating Officer
+14107109674
zhu(at)insilicomedicine(dot)com

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
http://www.prweb.com/releases/InSilico/Medicine/prweb11904553.htm

CONTACT: InSilico Medicine, Inc.
         Qingsong Zhu, PhD
         zhu@insilicomedicine.com
         +1 4107109674
 
Press spacebar to pause and continue. Press esc to stop.